Improved outcomes and precision medicine come within reach

P-080Incidence of thrombo-embolism (TE) during neo-adjuvant chemotherapy in patients (pts) with oesophago-gastric adenocarcinoma (OGC): implications for surgery and survival

(2016) R. Rulach et al.   ANNALS OF ONCOLOGY

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

(2016) Claire L Vale et al.   LANCET ONCOLOGY

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

(2016) Akash Kumar et al.   NATURE MEDICINE

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

(2016) Himisha Beltran et al.   NATURE MEDICINE

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

(2016) Freddie C. Hamdy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

(2016) Colin C. Pritchard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

(2016) Alexander W. Wyatt et al.   JAMA Oncology

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE